NICE says Provenge's cost was provided by the company, but is conditional on the treatment being launched and may be subject to change. NICE says any change will be reflected in the next iteration ...

Its prostate cancer immunotherapy vaccine Provenge initially promised great things when it was launched in the US in 2010, but its high price and competition from more convenient oral treatments ...

Provenge already looks like the product of a bygone era. The approval of Provenge is remarkable. It represents a triumph of esotericism over the scientific method; a victory for doggedness over ...

Pressure is mounting on the US Food and Drug Administration (FDA) to explain its decision to ignore an advisory committee's positive recommendation for the cancer vaccine Provenge. In the coming ...